This study is testing a digital app called PDAC-PATHWAYS, designed to provide information and support to patients starting neoadjuvant therapy (treatment given before surgery) for pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer. The study aims to see if it's practical and acceptable to use this app compared to usual care. You might be able to join if you are 18 or older, have newly diagnosed, non-metastatic PDAC, are starting neoadjuvant therapy within 8 weeks, and can speak and understand English. The main goals are to see how many people enroll and how many complete using the app over 10 weeks. The current recruitment status is unclear.

Study design

This is an interventional study with an unclear status, planning to enroll 50 participants. It's a pilot randomized controlled trial comparing the PDAC-PATHWAYS app to usual care.

What's involved

Participants will complete a baseline survey and then be assigned to either use the PDAC-PATHWAYS app or receive usual care. Feasibility and acceptability outcomes will be collected for 10 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 10 weeks to measure feasibility and intervention completion rates.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.